Wall Street Zen Downgrades Pulmonx (NASDAQ:LUNG) to Sell

Pulmonx (NASDAQ:LUNG) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Friday.

Several other equities research analysts have also recently weighed in on the stock. Wells Fargo & Company dropped their price target on shares of Pulmonx from $6.00 to $3.00 and set an “equal weight” rating for the company in a research report on Friday, August 1st. D. Boral Capital reissued a “buy” rating and set a $16.00 price target on shares of Pulmonx in a research report on Monday, September 8th. Stifel Nicolaus dropped their price target on shares of Pulmonx from $16.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, July 31st. Weiss Ratings reissued a “sell (e+)” rating on shares of Pulmonx in a research report on Saturday, September 27th. Finally, Piper Sandler lowered shares of Pulmonx from an “overweight” rating to a “neutral” rating and decreased their price objective for the stock from $9.00 to $2.50 in a report on Thursday, July 31st. Five equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $7.66.

Pulmonx Trading Up 8.9%

Shares of LUNG opened at $1.84 on Friday. The stock has a market capitalization of $74.98 million, a P/E ratio of -1.29 and a beta of 0.42. The company has a quick ratio of 4.63, a current ratio of 5.35 and a debt-to-equity ratio of 0.54. The firm has a fifty day simple moving average of $1.75 and a two-hundred day simple moving average of $3.24. Pulmonx has a twelve month low of $1.47 and a twelve month high of $9.37.

Pulmonx (NASDAQ:LUNG) last announced its quarterly earnings results on Wednesday, July 30th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.02. The business had revenue of $23.86 million during the quarter, compared to analysts’ expectations of $23.46 million. Pulmonx had a negative net margin of 62.88% and a negative return on equity of 69.76%. Pulmonx has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Pulmonx will post -1.55 EPS for the current year.

Institutional Trading of Pulmonx

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Deutsche Bank AG increased its stake in Pulmonx by 4.2% during the 1st quarter. Deutsche Bank AG now owns 1,147,105 shares of the company’s stock valued at $7,720,000 after purchasing an additional 46,116 shares in the last quarter. Parkman Healthcare Partners LLC increased its stake in Pulmonx by 194.4% during the 1st quarter. Parkman Healthcare Partners LLC now owns 611,875 shares of the company’s stock valued at $4,118,000 after purchasing an additional 404,022 shares in the last quarter. Bank of America Corp DE increased its stake in Pulmonx by 556.6% during the 2nd quarter. Bank of America Corp DE now owns 481,268 shares of the company’s stock valued at $1,246,000 after purchasing an additional 407,971 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Pulmonx by 1.7% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 320,946 shares of the company’s stock valued at $2,160,000 after acquiring an additional 5,414 shares during the last quarter. Finally, Essex Investment Management Co. LLC purchased a new stake in shares of Pulmonx during the 1st quarter valued at about $2,041,000. 91.04% of the stock is currently owned by institutional investors.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.